Navigation Links
New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients' Functionality and Quality of Life

SHENZHEN, China and SAN DIEGO, Calif., Sept. 6, 2011 /PRNewswire-Asia/ -- The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.  

The study was conducted at the Nanshan Affiliated Hospital of Guangdong Medical College in China, and included the participation of Beike Biotechnology Company (, China's leading stem cell research and regenerative medicine company, and the San Diego biotech company Medistem, Inc. (MEDS.PK).   The peer-reviewed article is available at: .

Dr. Shengqin Ye, CEO of Beike Biotechnology commented, "This is the first published study of the effects of adult stem cell treatments on patients with Hereditary Ataxia. The results should be enormously encouraging for those who suffer from this difficult condition.  With the combination of stem cells and physical therapy, study participants showed significant and sustained improvement. We are cautiously optimistic that further study will validate the efficacy and safety conclusions we have drawn from the study data."

Hereditary Ataxia is a neurodegenerative disorder characterized by atrophy of the cerebellum, brain stem, or spinal cord.  Manifestations of the condition include a variety of functional impairments relating to speech, walking, swallowing, and other physical activities.  Currently there is no cure for this condition.

Thomas Ichim, CEO of Medistem (MEDS.PK) stated, "The results of this important new study add to the growing body of published clinical research that suggests the efficacy of adult stem cell therapies, and points to their even greater potential in the future.  This study represents a significant step forward for both the scientific and patient communities, alike."

Over the course of the study, participants received 4-6 stem cell treatments via intravenous injection or by cervical or lumbar puncture, and underwent twice-daily 30-minute physical therapy sessions.  The study concluded, "In addition to the early effect seen in some subjects, the measured symptomatic improvements persisted throughout the period of the study, as noted with the follow-up data from a subset of subjects."  Study authors recommend further double blind placebo controlled studies to validate the efficacy, safety and long-term effects of the treatments.

About Beike Biotechnology Company:Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on the production of adult stem cells for use in medical therapies. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.  Currently, the stem cell therapies supported by Beike treat a variety of different medical conditions: ataxia, brain injury, cerebral palsy, lower limb ischemia, lupus, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve pathologies.For more information, please contact:Shenzhen Beike Biotechnology Company, Ltd.T. GutmannShenzhen Hi-Tech Industrial ParkTel:   +86-755-8630-9200Email: Web:

SOURCE Beike Biotechnology Co. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. RAND study finds increase in piracy and terrorism at sea
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
8. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
11. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
Post Your Comments:
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
Breaking Biology News(10 mins):